Scinai Publishes Financial Results and Provides Business Update; Shareholders’ Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

JERUSALEM, Nov. 22, 2024 /PRNewswire/ — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai”, or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices…